Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.31)
# 1,302
Out of 4,361 analysts
296
Total ratings
40.6%
Success rate
11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Reiterated: Buy | $56 | $28.85 | +94.11% | 19 | Jun 1, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintained: Buy | $88 | $57.33 | +53.50% | 9 | May 26, 2026 | |
| SRZN Surrozen | Maintained: Buy | $44 | $23.19 | +89.74% | 9 | May 26, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $17.13 | +156.86% | 12 | May 15, 2026 | |
| IMUX Immunic | Reiterated: Buy | $22 | $14.64 | +50.27% | 14 | May 14, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $8 | $3.99 | +100.50% | 34 | May 13, 2026 | |
| LENZ LENZ Therapeutics | Reiterated: Buy | $48 → $38 | $7.13 | +432.96% | 16 | May 12, 2026 | |
| ALDX Aldeyra Therapeutics | Reiterated: Hold | $2 | $1.64 | +21.95% | 31 | May 11, 2026 | |
| KOD Kodiak Sciences | Reiterated: Buy | $58 | $33.22 | +74.62% | 15 | May 11, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $36 | $9.27 | +288.35% | 31 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.9364 | +540.75% | 11 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $5.77 | +107.97% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $5.52 | +226.09% | 7 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $9.65 | +169.43% | 19 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $8 | $1.05 | +661.90% | 12 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.025 | - | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.70 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $9.60 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $6.52 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $68.00 | n/a | 5 | Oct 21, 2022 |
Mineralys Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $56
Current: $28.85
Upside: +94.11%
Tarsus Pharmaceuticals
May 26, 2026
Maintained: Buy
Price Target: $88
Current: $57.33
Upside: +53.50%
Surrozen
May 26, 2026
Maintained: Buy
Price Target: $44
Current: $23.19
Upside: +89.74%
Zenas BioPharma
May 15, 2026
Reiterated: Buy
Price Target: $44
Current: $17.13
Upside: +156.86%
Immunic
May 14, 2026
Reiterated: Buy
Price Target: $22
Current: $14.64
Upside: +50.27%
Opus Genetics
May 13, 2026
Reiterated: Buy
Price Target: $8
Current: $3.99
Upside: +100.50%
LENZ Therapeutics
May 12, 2026
Reiterated: Buy
Price Target: $48 → $38
Current: $7.13
Upside: +432.96%
Aldeyra Therapeutics
May 11, 2026
Reiterated: Hold
Price Target: $2
Current: $1.64
Upside: +21.95%
Kodiak Sciences
May 11, 2026
Reiterated: Buy
Price Target: $58
Current: $33.22
Upside: +74.62%
4D Molecular Therapeutics
May 11, 2026
Reiterated: Buy
Price Target: $36
Current: $9.27
Upside: +288.35%
May 8, 2026
Reiterated: Buy
Price Target: $6
Current: $0.9364
Upside: +540.75%
May 8, 2026
Reiterated: Buy
Price Target: $12
Current: $5.77
Upside: +107.97%
May 1, 2026
Reiterated: Buy
Price Target: $18
Current: $5.52
Upside: +226.09%
May 1, 2026
Reiterated: Buy
Price Target: $26
Current: $9.65
Upside: +169.43%
Apr 16, 2026
Maintained: Buy
Price Target: $80 → $8
Current: $1.05
Upside: +661.90%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.025
Upside: -
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $3.70
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: $9.60
Upside: n/a
Oct 29, 2024
Maintained: Buy
Price Target: $39
Current: $6.52
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $68.00
Upside: n/a